Lenvatinib is a multitarget tyrosine kinase inhibitor that inhibits the growth and angiogenesis of malignant cells by inhibiting the activation of multiple receptor tyrosine kinase signaling pathways, thereby effectively treating a variety of cancers. Here, NTRK1 is linked to cancer.